Coronavirus vaccine: DCGI grants emergency use nod to Covaxin, Corbevax, ZycovD for different age group of children

New Delhi: The Drugs Controller General of India (DCGI) on Tuesday approved three Covid vaccines for the restricted emergency use authorisation (EUA) for children of different age groups.

The DCGI gave the restricted emergency use authorisation to Bharat Biotech's Covaxin for children between the age of 6-12 years.

"The Hyderabad-based Pharma company Bharat biotech has been asked to submit safety data including the data on adverse events with due analysis every 15 days for the first two months and monthly thereafter up to 5 months by the Drug Controller General of India (DCGI)," Sources told ANI.

Read also: Study says Bharat Biotech Covaxin booster enhances antibody response against COVID variants including Omicron

In another development, the drug regulator approved restricted use in emergency situation for Biological E's Covid-19 vaccine Corbevax for children of 5 to 12 years age group.

Besides Corbevax and Covaxin, the DCGI also approved restricted use for emergency situation to ZycovD (Zydus Cadila vaccine) for children above the age of 12 years for a two-dose regimen.

Read also: Biological E gets CDSCO panel nod for Corbevax EUA for 5-11 years old

"India's fight against Covid more stronger! @CDSCO_INDIA_INF has approved Covaxin for 6 to 12 years of age group, Corbevax for 5 to 12 years age group of children and two doses ZyCoV-D for above 12 years of age group for Restricted Use in Emergency Situations," Union Health Minister Mansukh Mandaviya tweeted in Hindi.

This development comes after the Subject Expert Committee discussed recommendations for the restricted emergency use of Covaxin in children aged between 2-12 years.

However, the SEC, after a meeting on Thursday, has recommended restricted emergency use of Biological E's Covid-19 vaccine, Corbevax, in children aged 5-12 years.

Read also: DCGI panel asks Bharat Biotech to provide additional data on Covaxin for 2-12 years old